Baxter International Inc. (BAX)

90.01
NYSE : Health Technology
Prev Close 88.20
Day Low/High 87.85 / 90.11
52 Wk Low/High 69.10 / 95.19
Avg Volume 3.48M
Exchange NYSE
Shares Outstanding 508.84M
Market Cap 44.88B
EPS 2.00
P/E Ratio 46.18
Div & Yield 0.98 (1.02%)

Baxter: High EU Exposure, Compelling Chart

BAX looks attractive as long as it stays above $42.

Baxter's Rally Is Looking Tired

Baxter's Rally Is Looking Tired

The longer-term push is starting to lose steam and may need more consolidation than just a light-volume selloff.

Will Baxter International Break Out to New Highs?

Will Baxter International Break Out to New Highs?

Baxter will have to prove it can make a new high and still push higher.

Baxter upgraded at Piper

Baxter Could Finally Break Its Trading Range

Baxter Could Finally Break Its Trading Range

In the weekly chart, it's in the strongest technical position seen for a long time.

Shire to Acquire Biopharma Company Baxalta in $32B Deal

Shire to Acquire Biopharma Company Baxalta in $32B Deal

Ireland’s Shire has clinched Baxalta with a stock and cash deal worth $32 billion on Monday.

2 Stocks on the Verge of a Breakdown

2 Stocks on the Verge of a Breakdown

Health care names Merck and Baxter are troubling.

Stocks With Significant High Activity: the First Four Groups

Stocks With Significant High Activity: the First Four Groups

There are some good buying ideas among these stocks.

Jim Cramer Explains the Addition of PayPal to the Action Alerts PLUS Portfolio

Jim Cramer Explains the Addition of PayPal to the Action Alerts PLUS Portfolio

Jim Cramer, portfolio manager at Action Alerts PLUS, and research director, Jack Mohr sat down to talk about one of the charitable trust’s newest positions.

Baxalta Shares Spike Following Shire's $30.6B Takeover Offer

Baxalta Shares Spike Following Shire's $30.6B Takeover Offer

Drug manufacturer Baxalta (BXLT) was the best performing stock in the S&P 500 Tuesday after an unsolicited takeover offer from a competitor. The stock is TheStreet's Move of the Day.

Shire Proposes $30B Deal to Buy Disease Specialist Baxalta

Shire Proposes $30B Deal to Buy Disease Specialist Baxalta

Shire (SHPG) has announced an offer to buy Baxalta (BXLT), a rare disease treatment specialist based in the U.S., for around $30.6 billion in stock.

Sometimes, Breaking Up Is Smart to Do

Sometimes, Breaking Up Is Smart to Do

A company that divides itself can unlock value.

Baxter downgraded at Leerink

Gannett, Energizer in Focus Amid Huge Week For Corporate Spin-Offs

Gannett, Energizer in Focus Amid Huge Week For Corporate Spin-Offs

Beyond Greece, Puerto Rico and the June jobs report, Investors should also be aware of a big number of corporate spin-offs this week.

Baxter downgraded at Credit Suisse

Feeling Dizzy? Maybe It's From the Spinouts

Feeling Dizzy? Maybe It's From the Spinouts

These new companies may offer some intriguing opportunities.

Goldman Healthcare Conf.

Cramer: Intel Had to Be Aggressive With Altera, Don't Sell Amgen

Cramer: Intel Had to Be Aggressive With Altera, Don't Sell Amgen

Jim Cramer answers viewers' Twitter (TWTR) questions from the floor of the New York Stock Exchange.

Baxter's Spinoff Offers New Biotech Play

Baxter's Spinoff Offers New Biotech Play

Baxter Shareholders will also get stake in new firm Baxalta.

Baxter estimates, target cut at Leerink

Baxter downgraded at Morgan Stanley

Baxter Is Worth a Look

Baxter Is Worth a Look

We are not ready to pull the buy trigger yet.

Out of Baxter

I am selling my BAX long. I am selling my Baxter International (BAX) long based on my belief that the company might modestly miss fourth-quarter 2014 consensus expectations. If I am correct, this could lead to a guide down in 2015 expectations. More...

Looking Good for Baxter

The biotech deals augur well. Today's Roche/InterMune deal (and the other biotech deals reported in the last month) should augur well for Baxter's (BAX) spinoff into two companies. BAX is a conservative play that has lagged the market and still repr...

The Trader Daily

The Trader Daily

Monday's lack of symmetry puts this area back in play.

Finding Winning Charts Amid the Gloom

Finding Winning Charts Amid the Gloom

These quality names look appealing on the basis of 30-week moving average.